Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy

BJU International

Volumn 109, Issue SUPPL. 6, 2012, Pages 13-21

  Schulman, Claude ^a   Irani, J ^b   Aapro, M ^c  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Bone mineral density; Denosumab; Intermittent androgen deprivation therapy; Quality of life; Skeletal related events; Tolerability

Indexed keywords

ABARELIX; ALENDRONIC ACID; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; BUSERELIN; CYPROTERONE ACETATE; DEGARELIX; DENOSUMAB; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; NILUTAMIDE; PAMIDRONIC ACID; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TOREMIFENE; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BONE DISEASE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHRONIC DRUG ADMINISTRATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ANDROGEN ANTAGONISTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OSTEOPOROSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862168507     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11216.x     Document Type: Review

References (67)

1. Heidenreich A, Bastian PJ, Bellmunt J et al. Guidelines on prostate cancer. February 2012. Available from http://www.uroweb.org/gls/pdf/08-Prostate- Cancer.pdf [Accessed March 2012]
2. Tombal B. A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient. Urol Int 2009; 83: 373-8
3. Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW; ADT Survivorship Working Group. Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. J Sex Med 2010; 7: 2996-3010
4. Walker LM, Robinson JW. The unique needs of couples experiencing androgen deprivation therapy for prostate cancer. J Sex Marital Ther 2010; 36: 154-65
5. Grossmann M, Zajac JD. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf) 2011; 74: 289-93
6. Isbarn H, Boccon-Gibod L, Carroll PR et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009; 55: 62-75
7. Grossmann M, Zajac JD. Management of side effects of androgen deprivation therapy. Endocrinol Metab Clin North Am 2011; 40: 655-71
8. Dacal K, Sereika SM, Greenspan SL. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 2006; 54: 85-90
9. Schulman C. Intermittent hormone therapy: What is its place in clinical practice? Eur Urol Suppl 2009: 8: 852-6
10. Calais da Silva F. Intermittent hormonal therapy for prostate cancer. Current Opin Urol 2011; 21: 248-51
11. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. C ancer Res 1990; 5 0: 2275-82
12. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993; 71: 2782-90
13. Sato N, Gleave ME, Bruchovsky N et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996; 58: 139-46
14. Shaw GL, Wilson P, Cuzick J et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 2007; 99: 1056-65
15. Mottet N, Goussard M, Loulidi S, Wolff J. Intermittent versus continuous maximal androgen blockade in metastatic (D2) prostate cancer patients. A randomized trial. Eur Urol Suppl 2009; 8: 131 (abstr 44)
16. Buchan NC, Goldenberg SL. Intermittent versus continuous androgen suppression therapy: do we have consensus yet? C urr Oncol 2010; 17 (Suppl 2): S45-8
17. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010; 57: 49-59
18. Verhagen PCMS, Wissenburg LD, Wildhagen MF et al. Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer. Eur Urol Suppl 2008; 7: 206 (abstr 541)
19. Hussain M, Tangen CM, Higano C et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 3984-90
20. Calais da Silva FE, Goncalves F, Santos A et al. Evaluation of quality of life, side effects and duration of therapy in a phase 3 study on intermittent monotherapy versus continuous combined androgen deprivation. Eur Urol Suppl 2008; 7: 205 (abstr 540)
21. Calais da Silva J, Calais da Silva FE, Goncalves F et al. Phase III study of intermittent monotherapy versus continuous combined androgen deprivation. E ur Urol Suppl 2010; 9: 77 (abstr 142)
22. Calais da Silva FE, Bono AV, Whelan P et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 1269-77
23. Calais da Silva FM, Calais da Silva F, Bono A et al. Phase III study of intermittent MAB vs continuous MAB. J Urol 2011; 185: e288 (abstr 716)
24. Klotz L, O'Callaghan J, Ding K et al. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. J Clin Oncol Genitourinary Cancers Symposium 2011; 29 (7 suppl): abstr 3
25. de Leval J, Boca P, Yousef E et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002; 1: 163-71
26. Miller K, Steiner U, Lingnau A et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2007; 25 (18 suppl): abstr 5015
27. Tunn UW, Canepa G, Hillger H, Fuchs W. Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy-final results of a European randomized prospective phase-III clinical trial AUO study AP 06/95, EC 507. J Urol 2007; 177: 201 (abstr 600)
28. Langenhuijsen JF, Schasfoort EMC, Heathcote P et al. Intermittent androgen suppression in patients with advanced prostate cancer: an update of the TULP survival data. Eur Urol Suppl 2008; 7: 205 (abstr 538)
29. Shore ND, Crawford ED. Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol 2010; 12: 1-11
30. Crook JM, O'Callaghan J, Ding K et al. A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOGJPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2011; 29 (15 suppl): abstr 4514
31. De Conti P, Atallah AN, Arruda H, Soares BG, El Dib RP, Wilt TJ. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev 2007; Oct 17: CD005009
32. Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LALM, Witjes JA, Mulders PFA. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol 2011: epub ahead of print (Available from http://www.urologiconcology.org/article/S1078-1439(11)00089-5/abstract)
33. D'Amico AV, Chen MH, de Castro M et al. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol 2012; 13: 189-95
34. Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004; 46: 279-83
35. Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-8
36. Tombal B, Miller K, Boccon-Gibod L et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010; 57: 836-42
37. Boccon-Gibod L, van der Meulen E, Persson BE. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol 2011; 3: 127-40
38. Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab 1999; 84: 3431-4
39. Lee RJ, Saylor PJ, Smith MR. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer 2010; 8: 29-36
40. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 1219-22
41. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-6
42. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002; 87: 3656-61
43. Diamond TH, Bucci J, Kersley JH, Aslan P, Lynch WB, Bryant C. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol 2004; 172: 529-32
44. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64
45. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-903
46. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-55
47. Leder BZ, Smith MR, Fallon MA, Lee ML, Finkelstein JS. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 2001; 8 6: 511-6
48. Eriksson S, Eriksson A, Stege R, Carlström K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995; 57: 97-9
49. Berruti A, Dogliotti L, Terrone C et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002; 167: 2361-7
50. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 2008; 5: 24-34
51. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410-7
52. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57: 127-32
53. Morote J, Morin JP, Orsola A et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 2007; 69: 500-4
54. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-7
55. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-82
56. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416-24
57. Diamond TH, Winters J, Smith A et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001; 92: 1444-50
58. Michaelson MD, Kaufman DS, Lee H et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-42
59. Michael H, Härkönen PL, Kangas L, Väänänen HK, Hentunen TA. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol 2007; 151: 384-95
60. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 3841-6
61. Smith MR, Morton RA, Barnette KG et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010; 184: 1316-21
62. Smith MR, Malkowicz SB, Brawer MK, Hancock ML, Morton RA, Steiner MS. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol 2011; 186: 2239-44
63. Castellano D, Sepulveda JM, García-Escobar I, Rodriguez- Antolín A, Sundlöv A, Cortes-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist 2011; 16: 136-45
64. Smith MR, Egerdie B, Hernández Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-55
65. Smith MR, Saad F, Egerdie B et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009; 182: 2670-5
66. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-22
67. Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46